12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Promacta: Preliminary Phase III data

Preliminary data from the double-blind Phase III ENABLE 2 trial in 805 patients with HCV infection showed that Promacta plus standard of care (SOC; peginterferon alfa-2b and ribavirin) met the primary endpoint of a significantly greater proportion of patients achieving an SVR 24 weeks after the end of treatment vs. placebo plus SOC (19% vs. 13%, p=0.0202). Serious adverse events were reported in 20% of patients receiving Promacta...

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >